A detailed history of Bluestein R H & CO LLC transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Bluestein R H & CO LLC holds 5,700 shares of CRSP stock, worth $263,853. This represents 0.02% of its overall portfolio holdings.

Number of Shares
5,700
Previous 5,850 2.56%
Holding current value
$263,853
Previous $356,000 4.49%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$61.1 - $83.78 $9,165 - $12,567
-150 Reduced 2.56%
5,700 $372,000
Q2 2022

Aug 11, 2022

SELL
$43.23 - $73.83 $432 - $738
-10 Reduced 0.17%
5,850 $356,000
Q1 2022

May 11, 2022

SELL
$53.19 - $79.24 $22,073 - $32,884
-415 Reduced 6.61%
5,860 $368,000
Q4 2021

Feb 14, 2022

SELL
$70.09 - $111.29 $70,090 - $111,290
-1,000 Reduced 13.75%
6,275 $476,000
Q3 2021

Nov 12, 2021

SELL
$110.2 - $156.64 $523,450 - $744,039
-4,750 Reduced 39.5%
7,275 $814,000
Q2 2021

Aug 13, 2021

BUY
$100.84 - $161.89 $461,343 - $740,646
4,575 Added 61.41%
12,025 $1.95 Million
Q1 2021

May 12, 2021

BUY
$110.72 - $210.04 $99,648 - $189,036
900 Added 13.74%
7,450 $908,000
Q4 2020

Feb 12, 2021

BUY
$79.67 - $173.23 $67,719 - $147,245
850 Added 14.91%
6,550 $1 Million
Q3 2020

Nov 12, 2020

SELL
$78.5 - $100.64 $23,550 - $30,192
-300 Reduced 5.0%
5,700 $477,000
Q2 2020

Aug 12, 2020

SELL
$38.5 - $76.05 $2.91 Million - $5.75 Million
-75,642 Reduced 92.65%
6,000 $441,000
Q1 2020

May 12, 2020

BUY
$33.68 - $62.53 $2.4 Million - $4.45 Million
71,142 Added 677.54%
81,642 $3.46 Million
Q4 2019

Feb 13, 2020

BUY
$36.68 - $73.13 $124,712 - $248,641
3,400 Added 47.89%
10,500 $640,000
Q3 2019

Nov 13, 2019

SELL
$40.99 - $52.56 $16,396 - $21,024
-400 Reduced 5.33%
7,100 $291,000
Q2 2019

Aug 12, 2019

BUY
$35.45 - $48.2 $265,875 - $361,500
7,500 New
7,500 $353,000

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.61B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Bluestein R H & CO LLC Portfolio

Follow Bluestein R H & CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bluestein R H & CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bluestein R H & CO LLC with notifications on news.